title: A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine.
abstract: Delivery of therapeutic macromolecules is limited by the physiological limitations of the gastrointestinal tract including poor intestinal permeability, low pH and enzymatic activity. Several permeation enhancers have been proposed to enhance intestinal permeability of macromolecules; however their utility is often hindered by toxicity and limited potency. Here, we report on a novel permeation enhancer, Dimethyl palmitoyl ammonio propanesulfonate (PPS), with excellent enhancement potential and minimal toxicity. PPS was tested for dose- and time-dependent cytotoxicity, delivery of two model fluorescent molecules, sulforhodamine-B and FITC-insulin in vitro, and absorption enhancement of salmon calcitonin (sCT) in vivo. Caco-2 studies revealed that PPS is an effective enhancer of macromolecular transport while being minimally toxic. TEER measurements in Caco-2 monolayers confirmed the reversibility of the effect of PPS. Confocal microscopy studies revealed that molecules permeate via both paracellular and transcellular pathways in the presence of PPS. In vivo studies in rats showed that PPS enhanced relative bioavailability of sCT by 45-fold after intestinal administration. Histological studies showed that PPS does not induce damage to the intestine. PPS is an excellent permeation enhancer which provides new opportunities for developing efficacious oral/intestinal delivery systems for therapeutic macromolecules.
authors.affiliation: Department of Chemical Engineering, University of California, Santa Barbara 93106, USA.
authors.forename: Vivek
authors.initials: V
authors.lastname: Gupta
authors.forename: Byeong Hee
authors.initials: BH
authors.lastname: Hwang
authors.forename: Nishit
authors.initials: N
authors.lastname: Doshi
authors.forename: Samir
authors.initials: S
authors.lastname: Mitragotri
mesh_terms: D017738:Alkanesulfonic Acids / Q000737:chemistry* / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D018938:Caco-2 Cells; D002116:Calcitonin / Q000008:administration & dosage / Q000493:pharmacokinetics; D016650:Fluorescein-5-isothiocyanate / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005456:Fluorescent Dyes / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D007408:Intestinal Absorption / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D008297:Male; D010539:Permeability / Q000187:drug effects; D014677:Pharmaceutical Vehicles / Q000737:chemistry* / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D012235:Rhodamines / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D017738:Alkanesulfonic Acids; D005456:Fluorescent Dyes; D007328:Insulin; D014677:Pharmaceutical Vehicles; D012235:Rhodamines; C031573:insulin, fluorescein-isothiocyanated-; C022027:lissamine rhodamine B; C068559:propylsulfonic acid; C028815:salmon calcitonin; D002116:Calcitonin; D016650:Fluorescein-5-isothiocyanate
keywords: Caco-2; Calcitonin; Chemical permeation enhancer; Dimethyl palmitoyl ammonio propanesulfonate (PPS); Oral; Zwitterionic surfactant